As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

The targeting of the vaccine technology once considered revolutionary follows intense criticism by conservatives and ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

If Canada is serious about becoming a global powerhouse in fields such as AI and life sciences then this intrapreneur mindset ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...

Kennedy’s newest decision comes amid a string of vaccine pullbacks at the health department in recent months. In May, he said ...

The U.S. Department of Health and Human Services said it would wind down mRNA vaccine development activities under its biomedical research unit.

The Department of Health and Human Services plans to cancel contracts and pull funding for some vaccines being developed to ...

The US Department of Health and Human Services (HHS) plans to cancel $500m (£376m) in funding for mRNA vaccines being ...